LUND, Sweden, Dec. 14, 2020 /PRNewswire/
-- Immunovia AB (publ) ("Immunovia") today published the
link to the company's third webinar in a series on IMMray™
PanCan-d, Immunovia's test for early detection of pancreatic
cancer. The webinar will cover the IMMray™ PanCan-d verification
study results and its clinical use, including feedback from experts
in pancreatic cancer and pancreatic diseases.
Event Details:
Webinar No. 3 in Immunovia's IMMray™ PanCan-d Webinar Series:
Verification Study and Clinical Use
Date and Time: December 17,
2020 at 15:00 CET
Moderator for the webinar: CEO Patrik
Dahlen
Presenters: Thomas
King, MD, PhD; Linda Mellby,
PhD, VP R&D; and Laura Chirica,
CCO, PhD, Immunovia
The Immunovia team will host a live Q&A session immediately
following the webinar.
Link to live stream:
https://financialhearings.com/event/13559
Following the webinar, a recording will be available
on Immunovia's website: www.immunovia.com.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-publishes-link-to-webinar-no--3-on-immray--pancan-d--verification-study-and-clinical-use,c3254542
The following files are available for download:
https://mb.cision.com/Main/13121/3254542/1348295.pdf
|
Press release
(PDF)
|